Browse life science companies in Cambridge, home to one of Europe's leading biotechnology and life science ecosystems.
AI platform targeting chromosomal instability across cancer
Tailor Bio is a Cambridge-based biotechnology company developing an AI-driven precision medicine platform for cancers with chromosomal instability, a genomic phenomenon present in over 80% of all cancers. Founded from research originating at the Cancer Research UK Cambridge Institute, the company develops both…
GMP compliant Cell therapy CDMO
Advent Bioservices is a contract development and manufacturing organisation specialising in cell and gene therapy, operating GMP-certified facilities at Sawston, Cambridgeshire. The company offers process development, GMP manufacturing, quality control, and ultra-cold cryogenic storage services to biotech and drug…
AI imaging platform for lung and heart disease clinical trials
Qureight is a technology-driven imaging contract research organisation providing clinical data curation and AI-powered image analysis services to pharmaceutical and biotech companies. Its proprietary platform integrates CT imaging, biomarkers, and clinical metadata from complex respiratory and cardiovascular diseases,…
RNA-based therapeutics targeting neurodegenerative disease mechanisms
Harness Therapeutics is a Cambridge-based biotech developing oligonucleotide therapeutics that exploit post-transcriptional regulation to achieve controlled upregulation of disease-relevant proteins in the CNS. Its lead programme targets FAN1 nuclease in Huntington's disease to limit somatic DNA repeat expansion, with…
Global pharmaceutical company developing medicines across major disease areas
AstraZeneca is a multinational biopharmaceutical company engaged in the research, development, manufacture, and commercialisation of prescription medicines. Its pipeline and product portfolio span oncology, cardiovascular and metabolic disease, respiratory and immunology, rare diseases, and vaccines. The company…
Connected lab software and cell culture automation technology
Cell Culture Automation is a laboratory technology company developing software and instruments for cell culture research. Its live management platform integrates electronic notebooks, sample and inventory tracking, experimental records, equipment monitoring and budgeting. A plate-format environmental sensor monitors…
RNA trans-splicing gene therapies for aggressive cancers
Spliceor is a University of Cambridge spinout developing RNA trans-splicing gene therapies for aggressive cancers. Its platform is designed to produce therapeutic messenger RNA selectively in targeted cells by joining segments from different RNA molecules. Machine learning helps refine the constructs and optimise…
DUB inhibitor therapeutics targeting mitophagy and degenerative disease
Mission Therapeutics is a clinical-stage biotechnology company developing first-in-class small molecule inhibitors of deubiquitylating enzymes to treat diseases driven by mitochondrial dysfunction. By targeting a mitochondria-localised DUB, the company's drug candidates are designed to enhance mitophagy, the cellular…
AI-driven rescue and development of failed drug candidates
Ignota Labs is a biotechnology company that identifies, in-licenses and redevelops drug candidates that have failed clinical development due to toxicity. Using deep learning applied to cheminformatics and bioinformatics data, the company resolves the mechanistic basis of safety failures and makes targeted chemical…
Data-driven cis-bispecific antibody-drug conjugates for solid tumour cancers
Promatix Biosciences is an oncology drug discovery company developing next-generation bispecific antibody-drug conjugates through data-driven target pairing. Using a proteomics database and computational algorithms, the company identifies antigen combinations enabling selective tumour targeting, aiming to reduce…
Life sciences and technology campus south of Cambridge
Unity Campus is a life sciences and technology campus developed by Howard Group on the site of a former tannery at Pampisford, eight miles south of Cambridge, providing fully fitted laboratory and office space across a compact 11-acre site. Phase 2 expansion delivered 150,000 sq ft of new laboratory and office space…
Mitochondrial disease drug discovery subsidiary of Astellas Pharma
Astellas Engineered Small Molecules U.K. is a Cambridge-based drug discovery subsidiary of Astellas Pharma, operating as part of the company's Mitobridge Division alongside its US counterpart Mitobridge Inc. Originally founded as Nanna Therapeutics and acquired by Astellas in 2020, the entity applies a proprietary…
Handheld blood-electrolyte monitoring technology for kidney and cardiovascular care
Kalium Health is a medical technology company developing handheld blood-electrolyte monitoring for people with kidney and cardiovascular conditions. Its device is designed to measure potassium and other electrolytes from a single drop of blood using disposable test consumables, supporting monitoring outside…
Novel methylation amplification platform for clinical genomic diagnostics
Syndex Bio is a Cambridge-based biotechnology company developing a proprietary platform technology that enables amplification of DNA methylation for the first time. Unlike conventional PCR, which cannot preserve 5-methylcytosine signals, mcPCR copies both the four-base DNA code and its methylation patterns from…
Clinical-stage biotech developing treatments for multiple myeloma
CellCentric is a clinical-stage biopharmaceutical company developing inobrodib, a first-in-class oral inhibitor of the p300/CBP transcription co-activation proteins, for relapsed and refractory multiple myeloma. Inobrodib has been evaluated in over 400 patients and holds FDA Fast Track and orphan drug designations.…
Immuno-oncology therapies targeting the nfP2X7 cancer receptor
Biosceptre is a UK-headquartered clinical-stage biotechnology company developing cancer therapeutics based on its proprietary nfP2X7 platform. The nfP2X7 receptor is a non-functional form of P2X7 expressed on cancer cells across a broad range of tumour types, enabling targeted therapeutic approaches. The pipeline…
Precision small molecule drugs for obsessive-compulsive disorder
Serenatis Bio is a preclinical-stage biotech developing small molecule drugs to treat obsessive-compulsive disorder (OCD). Its pipeline of three candidates targets distinct neurological mechanisms, including glutamate, AMPA, and dopamine pathways, with a biomarker-driven approach designed to match patients to…
Mixed-use science and technology park near Cambridge
Vision Park is a science, technology and finance business park located in Histon, approximately three miles north of Cambridge city centre. The park hosts a diverse range of tenants across life sciences, technology and professional services, with life science occupants including pharmaceutical, genomics, biotech…
Cambridge campus uniting biomedical research, hospitals and life sciences
Cambridge Biomedical Campus is a life sciences and healthcare campus bringing together hospitals, research institutes, universities and biotechnology companies. The site integrates clinical care, academic research and pharmaceutical development, enabling collaboration across drug discovery, translational medicine and…
Large-scale genomics research institute advancing human and pathogen biology
The Wellcome Sanger Institute is a genomics research institute on the Wellcome Genome Campus in Hinxton, funded by Wellcome. It made the largest single contribution to the Human Genome Project and has since expanded across cancer genomics, cellular genetics, infectious disease and parasitology. Research programmes…